Dextrin Or Derivative Patents (Class 514/58)
  • Patent number: 10682375
    Abstract: The present invention generally relates to iron-polysaccharide (polydextrose) complexes and methods for the preparation thereof. In particular, the present invention relates to iron-polydextrose complexes and methods for the preparation thereof. The inventive complexes are suitable for use in various compositions, including particulate compositions that may be incorporated in various forms of administration, including tablets, capsules, and intravenous formulations. The complexes and compositions of the present invention are suitable for use in the treatment of iron deficient anemia. Advantageously, in addition to providing iron supplementation the complexes and compositions of the present invention provide certain advantages based on the presence of polydextrose (e.g., its low glycemic index and high fiber content).
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: June 16, 2020
    Assignee: Particle Dynamics International, LLC
    Inventors: Paul Brady, Keith Cromack
  • Patent number: 10668160
    Abstract: An inhalable dry powder formulation containing SAE-CD and an active agent is provided. The formulation is adapted for administration by DPI. The SAE-CD serves as a carrier rather than as an absorption enhancer. The average particle size of the SAE-CD is large enough to preclude (for the most part) pulmonary deposition thereof. Following release from the DPI device, the SAE-CD-containing particles dissociate from the active agent-containing particles in the buccal cavity or throat, after which the active agent-containing particles continue deeper into the respiratory tract. The physicochemical and morphological properties of the SAE-CD are easily modified to permit optimization of active agent and carrier interactions. Drugs having a positive, neutral or negative electrostatic charge can be delivered by DPI when SAE-CD is used as a carrier.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: June 2, 2020
    Assignee: CyDex Pharmaceuticals, Inc.
    Inventors: James D. Pipkin, Gerold L. Mosher, Douglas B. Hecker
  • Patent number: 10646439
    Abstract: Disclosed herein is an aqueous pharmaceutical formulation comprising about 10 mg/mL of propofol, 175 mg/mL of sulfobutylether ?-cyclodextrin, a citric buffer, wherein the composition has a pH of about 5.5. Also disclosed is a method of inducing and maintaining anesthesia or sedation in a patient by administering the aqueous pharmaceutical formulation.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: May 12, 2020
    Assignee: Cuda Anesthetics, LLC
    Inventor: Christopher Mengler
  • Patent number: 10639305
    Abstract: A liquid preparation includes an etherified cyclodextrin derivative and a substituted benzimidazol, where the etherified cyclodextrin derivative is one of alpha-, beta, and gamma-cyclodextrin ether.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: May 5, 2020
    Inventors: Martin Folger, Stefan Lehner
  • Patent number: 10624830
    Abstract: A cosmetic composition and a method of preparing a cosmetic composition that includes mangiferin characterized as demonstrating soluble and chemically stable mangiferin, wherein stability includes resistance to crystallization of mangiferin that is independent of temperature and pH.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: April 21, 2020
    Assignee: L'OREAL
    Inventors: Yang Deng, Zhi Pan, Anne-Laure Suzanne Bernard, Shan Wu
  • Patent number: 10588921
    Abstract: Provided is a pharmaceutical composition for the treatment of disorders such as Niemann-Pick disease and GM1 gangliosidosis which are caused by the storage of cholesterol, such as lysosomal storage disease. Also provided is a method for screening for said pharmaceutical compositions that uses iPS cell strains that phenocopy phentotypes of these disorders. Provided is a pharmaceutical composition for the treatment and/or prevention of lysosomal storage disease, characterized by containing hydroxypropyl-?-cyclodextrin as an active ingredient. Also provided are an iPS cell strain derived from patients suffering from intractable disorders and prepared using a new temperature-sensitive Sendai virus vector, and a screening method for pharmaceuticals using said iPS cell strain.
    Type: Grant
    Filed: December 3, 2014
    Date of Patent: March 17, 2020
    Assignee: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY
    Inventors: Takumi Era, Tetsumi Irie
  • Patent number: 10533061
    Abstract: A hyaluronic acid product including a cross-linked hyaluronic acid and one or more cyclodextrin molecules. The hyaluronic acid is cross-linked by ether bonds, and the one or more cyclodextrin molecules are grafted onto the cross-linked hyaluronic acid by amide bonds, preferably using a triazine-based coupling reagent. A process of preparing a hyaluronic acid product including a cross-linked hyaluronic acid and one or more cyclodextrin molecules.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: January 14, 2020
    Assignee: Galderma S.A.
    Inventors: Jean-Guy Boiteau, Elin Säwén
  • Patent number: 10526422
    Abstract: The present invention provides a process for the preparation of (6-per-deoxy-6-per-(2-carboxyethyl)thio-?-cyclodextrin) sodium salt, comprising the steps of: reacting ?-cyclodextrin (SM1) with iodine in the presence of triphenylphosphine in an organic solvent to afford an intermediate, 6-per-deoxy-6-iodo-?-cyclodextrin (abbreviated as SGMD-1); adding methanol solution of sodium methoxide into the reaction system followed by the addition of acetone without removal of the solvent under reduced pressure to obtain the crude SGMD-1 as a solid after filtration; purifying the crude SGMD-1 by recrystallization; reacting a obtained recrystallized intermediate (SGMD-1) with 3-mercaptopropionic acid in basic medium e.g., sodium hydride, to obtain the crude 6-per-deoxy-6-per-(2-carboxyethyl)thio-?-cyclodextrin sodium salt (abbreviated as SGMD); purifying the crude SGMD by passing through adsorbents followed by recrystallization.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: January 7, 2020
    Assignee: BEIJING CREATRON INSTITUTE OF PHARMACEUTICAL RESEARCH CO., LTD.
    Inventors: Huijuan Jia, Yan Chen, Xiangwei Liu
  • Patent number: 10463687
    Abstract: The present invention relates to the use of cyclic oligosaccharides as chemical complexants of lipofuscin bisretinoids (A2E) to prevent and treat eye (i.e., retinal or macular) disease. Monomeric, dimeric, multimeric, or polymeric oligosaccharide rings act as pharmacologic agents to prevent and treat ophthalmologic disorders triggered by the accumulation of lipofuscin in the retinal pigment epithelium (RPE), which occurs as a consequence of either genetic disorders, such as Stargardt Disease (SD) and Best Disease (BD), or aging, such as Age-Related Macular Degeneration (AMD), or other diseases, such as retinitis pigmentosa, and cone-rod dystrophy.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: November 5, 2019
    Assignee: CORNELL UNIVERSITY
    Inventors: Enrique Rodriguez-Boulan, Marcelo Nociari
  • Patent number: 10426744
    Abstract: Pharmaceutical compositions for treating, mitigating or preventing fungal nail diseases, disorders or pathologies are described, the compositions comprising at least one functionalized allylamine compound, at least one functionalized triazole compound, and at least one functionalized imidazole compound. Methods for fabricating the compositions and using them are also described.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: October 1, 2019
    Assignee: Harrow Health, Inc.
    Inventor: Dennis Elias Saadeh
  • Patent number: 10412960
    Abstract: Microparticles and nanoparticles of hydrophobized polysaccharide and an alpha-cyclodextrin, obtained by self-association in an aqueous medium, the hydrophobized polysaccharide being obtained by grafting of alkyl chains derived from fatty acids, by an acylation reaction. These microparticles and nanoparticles constitute systems used for encapsulating substances of interest, in particular in the pharmaceutical field, and vectorization thereof for therapeutic purposes.
    Type: Grant
    Filed: April 5, 2013
    Date of Patent: September 17, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE PARIS-SUD
    Inventor: Kawthar Bouchemal
  • Patent number: 10363214
    Abstract: Compositions and methods for treating dry age related macular degeneration (dry AMO) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA).
    Type: Grant
    Filed: July 7, 2014
    Date of Patent: July 30, 2019
    Assignee: Allergan, Inc.
    Inventors: Scott M. Whitcup, Michael R. Robinson, Wendy M. Blanda, Patrick M. Hughes, James A. Burke
  • Patent number: 10342816
    Abstract: The invention concerns topical ophthalmic preparations in the form of eye-drops in aqueous solution, containing azithromycin (or a pharmacologically acceptable salt thereof) as active ingredient, wherein the azithromycin is solubilized and stabilized by means of ?-cyclodextrins, and in particular by means of the ?-cyclodextrin called sulfobutyl ether ?-cyclodextrin (SBE-?-CD). The proposed preparations have a remarkably high stability, both physical and chemical, which enables its storage at room temperature for the envisaged period of validity for a commercial pharmaceutical product.
    Type: Grant
    Filed: May 6, 2014
    Date of Patent: July 9, 2019
    Assignee: MEDIVIS S.R.L.
    Inventors: Danilo Aleo, Maria Grazia Antonietta Saita, Barbara Melilli, Sergio Mangiafico, Melina Cro
  • Patent number: 10314848
    Abstract: The invention relates to the field of male and/or female sexual dysfunction. The invention specifically relates to the use of testosterone and a 5-HT1A agonist.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: June 11, 2019
    Assignee: EB IP LYBRIDOS B.V.
    Inventors: Jan Johan Adriaan Tuiten, Johannes Martinus Maria Bloemers, Robertus Petrus Johannes De Lange
  • Patent number: 10278979
    Abstract: The present invention provides a therapeutic composition for intractable leukemia comprising a drug (a) and a drug (b), wherein the drug (a) is a compound represented by the following formula (I), a salt thereof, or a prodrug thereof: wherein, Ar1 is a substituted or unsubstituted arylene group; Ar2 is a substituted or unsubstituted aryl group or a substituted or unsubstituted aralkyl group; L is an oxygen atom, —NHCO—, or —CONH—; X1 is CH; X2 and X3 are CH and a nitrogen atom, respectively; Y is an ethylene group; m is 0; and Z1 and Z2 form a substituted or unsubstituted monocyclic heterocyclic group comprising X3 and having two nitrogen atoms as ring members, and the drug (b) is a steroidal anti-inflammatory drug; and relates to a therapy for intractable leukemia.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: May 7, 2019
    Assignee: RIKEN
    Inventors: Fumihiko Ishikawa, Yoriko Saito
  • Patent number: 10273313
    Abstract: The present invention relates to multimeric mannosides, a process for preparing the same and their uses in medicine for treating Escherichia coli infections.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: April 30, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE NANTES, UNIVERSITE DE PICARDIE JULES VERNE, UNIVERSITE LILLE 1-SCIENCES ET TECHNOLOGIES, UNIVERSITE D'AUVERGNE
    Inventors: Julie Bouckaert, Sebastien Gouin, David Deniaud, Rostyslav Bilyy, Tetiana Dumych, Adeline Sivignon, Arlette Darfeuille-Michaud
  • Patent number: 10266611
    Abstract: Describes cooperative hybrid complexes of hyaluronic acid, a simple and economical method for production thereof and use thereof in the area of medicine, cosmetics and food.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: April 23, 2019
    Assignee: ALTERGON S.A.
    Inventors: Mario De Rosa, Antonella D'Agostino, Annalisa La Gatta, Chiara Schiraldi
  • Patent number: 10246524
    Abstract: A method for preparing sulfobutyl ether-?-cyclodextrin. ?-cyclodextrin and 1,4-sulfobutyrolactone are used as raw materials, and a proper amount of an organic solvent is introduced into an alkaline aqueous solution, so that the solubility of the 1,4-sulfobutyrolactone is increased, and the synthesis yield of the sulfobutyl ether-?-cyclodextrin is improved. Operations including ultrasonic dialysis, active carbon decoloration, freeze-drying and so on are performed on the obtained product solution, so as to obtain a powder product of the sulfobutyl ether-beta-cyclodextrin.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: April 2, 2019
    Assignee: ASYMCHEM LABORATORIES (TIANJIN) CO., LTD.
    Inventors: Hao Hong, Changfeng Li, Litao Shen
  • Patent number: 10239961
    Abstract: The invention provides a method for preparing sulphoalkyl ether-?-cyclodextrin. The method comprises first contacting cyclodextrin with a base to form activated cyclodextrin. The method then comprises separately contacting the activated cyclodextrin with an alkyl sultone to form sulphoalkyl ether-?-cyclodextrin. The activation reaction is carried in batch and the sulphoalkylation reaction is carried out under continuous flow conditions.
    Type: Grant
    Filed: September 30, 2015
    Date of Patent: March 26, 2019
    Assignee: CURADEV PHARMA PRIVATE LIMITED
    Inventors: Tammy Savage, Stephen Wicks, John Mitchell
  • Patent number: 10233263
    Abstract: The present invention provides a method for improved preparation of Sugammadex sodium.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: March 19, 2019
    Assignee: FORMOSA LABORATORIES, INC.
    Inventors: Yu-Liang Liu, Ching-Peng Wei
  • Patent number: 10159752
    Abstract: An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: December 25, 2018
    Assignee: CyDex Pharmaceuticals, Inc.
    Inventors: James D. Pipkin, Rupert O. Zimmerer, Diane O. Thompson, Gerold L. Mosher
  • Patent number: 10130639
    Abstract: This application is directed to a homogeneous solution of an aqueous, topical composition useful for the treatment of infection and/or for the treatment of inflammation due to trauma to tissue. Specifically, this application relates to a homogeneous, aqueous composition of a quinolone antibiotic and an anti-inflammatory agent.
    Type: Grant
    Filed: September 5, 2015
    Date of Patent: November 20, 2018
    Inventor: Randal Davis
  • Patent number: 10117940
    Abstract: An inhalable dry powder formulation containing SAE-CD and an active agent is provided. The formulation is adapted for administration by DPI. The SAE-CD serves as a carrier rather than as an absorption enhancer. The average particle size of the SAE-CD is large enough to preclude (for the most part) pulmonary deposition thereof. Following release from the DPI device, the SAE-CD-containing particles dissociate from the active agent-containing particles in the buccal cavity or throat, after which the active agent-containing particles continue deeper into the respiratory tract. The physicochemical and morphological properties of the SAE-CD are easily modified to permit optimization of active agent and carrier interactions. Drugs having a positive, neutral or negative electrostatic charge can be delivered by DPI when SAE-CD is used as a carrier.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: November 6, 2018
    Assignee: CYDEX PHARMACEUTICALS, INC.
    Inventors: James D. Pipkin, Gerold L. Mosher, Douglas B. Hecker
  • Patent number: 10085949
    Abstract: A method for producing a flurane complex, comprising the steps of producing an aqueous solution of sulfobutylether-?-cyclodextrin (SBECD); controlling the temperature of said solution to a temperature of from 2 to 15° C.; adding the flurane to the aqueous solution; allowing the solution to react to produce the complex; and separating the complex.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: October 2, 2018
    Assignee: Sapiotec GmbH
    Inventors: Norbert Roewer, Jens Broscheit
  • Patent number: 10052305
    Abstract: In various embodiments methods and composition are provided for the treatment and/or prophylaxis of cystinuria. In certain embodiments the methods involve administering to a mammal in need thereof (e.g., identified as at risk for, or having cystinuria) an effective amount of lipoic acid and/or one or more lipoic acid derivatives.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: August 21, 2018
    Assignee: BUCK INSTITUTE FOR RESEARCH ON AGING
    Inventors: Tiffany Zee, Marshall L. Stoller, Pankaj Kapahi
  • Patent number: 10010542
    Abstract: A novel compound, (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one, is provided herein. (E)-1-(pyridyn-4-yl)-3-(7-(trifluoromethyl)quinolin-2-yl)-prop-2-en-1-one is an inhibitor of 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) with surprisingly superior efficacy and pharmacodynamic properties in vitro and in vivo. Also provided are pharmaceutical compositions including the compound and methods of use of the compound in treating cancer and tumors in vivo, as well as inhibiting glycolytic flux and PFKFB3 enzymatic activity in cells.
    Type: Grant
    Filed: May 9, 2017
    Date of Patent: July 3, 2018
    Assignee: GB ACT, INC.
    Inventors: Gilles H. Tapolsky, Pooran Chand
  • Patent number: 9968636
    Abstract: The present invention relates to a peritoneal dialysis fluid comprising a compound inhibiting glycogen synthase kinase (GSK)-3 activity, in particular (GSK)-3? activity, for use in the prevention of infectious and non-infectious peritoneal complications such as peritonitis, peritoneal membrane injury, damage and failure, barrier dysfunction and mesothelial cell detachment.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: May 15, 2018
    Assignee: ZYTOPROTEC GMBH
    Inventors: Krisztina Szilvia Rusai, Christoph Aufricht
  • Patent number: 9855228
    Abstract: Disclosed herein is an oral pharmaceutical composition in the form of an aqueous solution of atomoxetine as an active ingredient. The aqueous solution of atomoxetine comprises a taste-masked liquid carrier comprising peppermint, orange flavor and a viscosity agent. The combined flavors successfully masked atomoxetine hydrochloride's bitter smell and/or taste which makes it a novel palatable pharmaceutical composition. The viscosity agent improves the oral pharmaceutical composition's consistency and provides a smooth texture which makes it easy to swallow. More specifically, the oral pharmaceutical composition comprises effective amounts of: (a) atomoxetine or the pharmaceutically acceptable salts thereof; and (b) a taste-masked liquid carrier. Also provided is a method for making the aqueous solution of atomoxetine. The present disclosure also provides methods of using oral pharmaceutical composition for the treatment of a subject having a disorder treatable by the administration of atomoxetine.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: January 2, 2018
    Assignee: TAHO PHARMACEUTICALS LTD.
    Inventors: Chin Chung Lin, Chien-Chiao Wang, Catherine Lee
  • Patent number: 9827324
    Abstract: An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use solution, or concentrated composition. The formulation is employed in an improved nebulization system for administering corticosteroid by inhalation. SAE-CD present in the formulation significantly enhances the chemical stability of budesonide. A method of administering the formulation by inhalation is provided. The formulation can also be administered by conventional nasal delivery apparatus.
    Type: Grant
    Filed: August 15, 2012
    Date of Patent: November 28, 2017
    Assignee: Cydex Pharmaceuticals, Inc.
    Inventors: James D. Pipkin, Rupert O. Zimmerer, Diane O. Thompson, Gerold L. Mosher
  • Patent number: 9770407
    Abstract: The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration.
    Type: Grant
    Filed: October 11, 2013
    Date of Patent: September 26, 2017
    Assignee: LUNDBECK PHARMACEUTICALS LLC
    Inventors: James Cloyd, Angela Birnbaum, Ilo Leppik, Stephen D. Collins
  • Patent number: 9649387
    Abstract: Personal care products are provided. An exemplary personal care product includes a composition that is applied to the body or clothing, or an article applied against the body; a plurality of particles associated with the composition or a component of the article, the plurality of particles, at least some of the plurality of particles comprising a cyclodextrin complexing material and a first fragrance material, wherein the percent of the first fragrance material that is complexed with the cyclodextrin is greater than about 90%, so that the perceptibility of the first fragrance is minimized prior to its release; and a second fragrance material that is not complexed with the cyclodextrin and that is different from the first fragrance material, wherein the composition or article does not contain an antiperspirant active.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: May 16, 2017
    Assignee: The Procter & Gamble Company
    Inventors: Timothy Alan Scavone, Michael Jude Leblanc, Lowell Alan Sanker, Adrian Gregory Switzer
  • Patent number: 9649386
    Abstract: Personal care products are provided. An exemplary personal care product includes a composition that is applied to the body or clothing, or an article applied against the body; a plurality of particles associated with the composition or a component of the article, the plurality of particles, at least some of the plurality of particles comprising a cyclodextrin complexing material and a first fragrance material, wherein the percent of the first fragrance material that is complexed with the cyclodextrin is greater than about 90%, so that the perceptibility of the first fragrance is minimized prior to its release; and a second fragrance material that is not complexed with the cyclodextrin and that is different from the first fragrance material, wherein the composition or article does not contain an antiperspirant active.
    Type: Grant
    Filed: May 5, 2011
    Date of Patent: May 16, 2017
    Assignee: The Procter & Gamble Company
    Inventors: Timothy Alan Scavone, Michael Jude Leblanc, Lowell Alan Sanker, Adrian Gregory Switzer
  • Patent number: 9629797
    Abstract: The present invention is directed to a carbamazepine-cyclodextrin inclusion complex useful for the parenteral administration of carbamazepine. The carbamazepine-cyclodextrin inclusion complex is prepared by the admixture of a modified cyclodextrin and carbamazepine in a physiologically acceptable fluid. Modified cyclodextrins include 2-hydroxypropyl-beta-cyclodextrin and sulfoalkyl cyclodextrins. More particularly, the sulfoalkyl cyclodextrins are those described and disclosed in U.S. Pat. Nos. 5,134,127 and 5,376,645. A physiologically acceptable fluid includes sterile isotonic water, Ringer's lactate, D5W (5% dextrose in water), physiological saline, and similar fluids suitable for parenteral administration.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: April 25, 2017
    Assignee: LUNDBECK PHARMACEUTICALS LLC
    Inventors: James Cloyd, Angela Birnbaum, Ilo Leppik, Stephen D. Collins
  • Patent number: 9615575
    Abstract: Composition for elimination of troublesome varmints comprises all the non-essential amino acids alanine, glycine, proline, serine, tyrosine, aspartic acid, asparagine, glutamic acid.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: April 11, 2017
    Assignee: Determinants of Metabolism Research Laboratory S.r.l.
    Inventor: Francesco Saverio Dioguardi
  • Patent number: 9610280
    Abstract: The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides Tmax value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a Tmax substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: April 4, 2017
    Assignee: DR. REDDY'S LABORATORIES LIMITED
    Inventors: Rajesh Gandhi, Sreekanth Manikonda, Arun Jana, Sameer Shrinivas Kunte
  • Patent number: 9610360
    Abstract: Described herein is a cyclodextrin containing polymer conjugate.
    Type: Grant
    Filed: June 20, 2013
    Date of Patent: April 4, 2017
    Assignee: CERULIEAN PHARMA INC.
    Inventors: Mark E. Davis, Jungyeon Hwang, Tianyi Ke, Ching-jou Lim, Thomas Schluep
  • Patent number: 9549994
    Abstract: Compositions of an inclusion complex of nicardipine or a pharmaceutically acceptable salt thereof and a sulfoalkylated ?-cyclodextrin. The compositions being formulated for parenteral bolus administration to a human subject. The compositions being useful in the treatment of cardiovascular and cerebrovascular disorders.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: January 24, 2017
    Assignee: EKR Therapeutics, Inc.
    Inventors: Supriya Gupta, Yanli Mi, Camellia Zamiri
  • Patent number: 9522197
    Abstract: The invention relates to nanoparticles comprising a biodegradable polymer, a cyclodextrin or a derivative thereof, and a biologically active molecule. Said nanoparticles can associate large amounts of biologically active molecules, especially of a hydrophobic nature, and release the biologically active molecule providing sustained and constant plasma levels thereof when they are administered orally or through any other mucosa of the organism.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: December 20, 2016
    Assignee: INNOUP FARMA, S.L.
    Inventors: Maite Agüeros Bazo, Hesham H. A. Salman, Juan Manuel Irache Garreta, Miguel Angel Campanero Martínez
  • Patent number: 9504646
    Abstract: The disclosure provides compositions for treating an ocular condition. The composition comprises a physiologically effective amount of an androgen, wherein the composition is suitable for topical administration to an eye. The disclosure further provides methods for treating an ocular condition with the disclosed compositions.
    Type: Grant
    Filed: August 31, 2015
    Date of Patent: November 29, 2016
    Assignee: Allergan, Inc.
    Inventors: John T. Trogden, Adnan K. Salameh, Chetan P. Pujara, Anuradha V. Gore, Jaya Giyanani
  • Patent number: 9493583
    Abstract: A novel anionic polysaccharides functionalized by at least one hydrophobic acid derivative. These novel anionic polysaccharides including hydrophobic groups have good biocompatibility and their hydrophobicity can be easily adjusted without detrimentally affecting the biocompatibility or the stability. A method of synthesis which makes it possible to produce them and to pharmaceutical compositions including them.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: November 15, 2016
    Assignee: ADOCIA
    Inventors: Richard Charvet, Remi Soula, Olivier Soula
  • Patent number: 9490144
    Abstract: A quaternary ammonium salt compound is represented by the following formula (A-1), wherein, R1, R2, and R3 each represent an alkyl group, an alkenyl group, an aryl group, or an aralkyl group, a part or all of hydrogen atoms in these groups may be substituted by a hydroxyl group(s), an alkoxy group(s), or a halogen atom(s), and these groups may include one or more of a carbonyl group and an ester bond; R4 represents a single bond, an alkylene group, an alkenylene group, an arylene group, or an aralkylene group, a part or all of hydrogen atoms in these groups may be substituted by an alkoxy group(s) or a halogen atom(s), and these groups may include one or more of an ether bond, a carbonyl group, an ester bond, and an amide bond; and A? represents a non-nucleophilic counter ion.
    Type: Grant
    Filed: April 7, 2015
    Date of Patent: November 8, 2016
    Assignee: SHIN-ETSU CHEMICAL CO., LTD.
    Inventors: Tsutomu Ogihara, Takeru Watanabe
  • Patent number: 9446058
    Abstract: The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelitiasis mainly with cholesterol stones, alcoholic and non-alcoholic steatohepatitis, biliary cirrhosis, cholesterol imbibition gallbladder and drug-induced and toxic liver damage. The pharmaceutical composition is administered by mouth and contains a hepatoprotector and a prebiotic taken, as an active agent, in therapeutically effective doses. The invention contributes to the liver's functional recovery in a short time and prevents disease recidivation owing to the recovery of cholesterol exchange and intestinal biocenosis as a result of the synergistic interaction of a hepatoprotector and a prebiotic, thereby also preventing hepatoprotector side effects.
    Type: Grant
    Filed: March 4, 2008
    Date of Patent: September 20, 2016
    Inventors: Aleksander Vladimirovich Dikovskiy, Boris Anatolievich Rudoy, Oleg Valentinovich Dorozhko
  • Patent number: 9409896
    Abstract: The present invention relates to carrier systems useful for pharmaceutical compositions. These carriers comprise an emulsifier, and also in further embodiments a polymeric dissolution aid. These carriers are useful for delivering pharmaceutical actives such as antimicrobial agents.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: August 9, 2016
    Assignee: Melinta Therapeutics, Inc.
    Inventors: Eric S. Burak, Danping Li, David S. Dresback
  • Patent number: 9382224
    Abstract: The present invention relates to chromen-4-one derivatives of the formula (I), to the use thereof as self-tanning substance or for increasing melanin synthesis, improving melanin transport and/or improving the distribution of melanin in suprabasal layers, and to preparations comprising these chromen-4-one derivatives.
    Type: Grant
    Filed: December 27, 2011
    Date of Patent: July 5, 2016
    Assignee: MERCK PATENT GMBH
    Inventors: Christophe Carola, Rene Peter Scheurich
  • Patent number: 9375401
    Abstract: Ophthalmic compositions comprising 0.005 wt. % to 2.0 wt. % of alkoxylated natural waxes selected from the group consisting of alkoxylated lanolin and alkoxylated jojoba, and a method of treating a patient diagnosed with dry eye syndrome, or for cleaning and disinfecting contact lenses, with the ophthalmic compositions.
    Type: Grant
    Filed: January 10, 2013
    Date of Patent: June 28, 2016
    Assignee: Bausch ÷ Lomb Incorporated
    Inventors: Erning Xia, Krista Fridman
  • Patent number: 9283246
    Abstract: The present invention relates to pharmaceutical compositions containing carboxylated starch derivatives as well a their use as osmotics in particular for use in the treatment of chronic renal failure by dialysis.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: March 15, 2016
    Assignee: FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH
    Inventors: Dominik Fenn, Thomas Schweitzer
  • Patent number: 9233995
    Abstract: Quinazoline derivatives represented by general formula (1) and quinazoline complexes as protein kinase inhibitors, and their preparation methods are provided. Wherein, in general formula (1), at least one of R and R? is a group containing an atom capable of coordinating with noble metals, m and n are either the same or different and are integers from 0 to 5. Said quinazoline complex as protein kinase inhibitor is formed by coordination compound containing noble metal and said quinazoline derivative ligand capable of coordinating with noble metal in the coordination compound.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: January 12, 2016
    Assignee: INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES
    Inventors: Fuyi Wang, Qun Luo, Liyun Ji, Wei Zheng, Shuang Lv, Xianchan Li
  • Patent number: 9192669
    Abstract: The present invention relates to the use of a combination of a PDE5-inhibitor and testosterone for the preparation of a medicament for the treatment of Female Sexual Dysfunction.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: November 24, 2015
    Assignee: EB IP LYBRIDO B.V.
    Inventor: Jan Johan Adriaan Tuiten
  • Patent number: 9149536
    Abstract: Provided herein are antimicrobial conjugates of two antibiotic agents, exhibiting improved activity also against resistant bacteria, compared to each of the agents separately or their mixture, and having substantially no resistance emerged thereagainst, as well as processes for preparation the same, compositions containing the same, and uses thereof in medical treatments against pathogenic microorganisms. The disclosed antimicrobial conjugates are composed of aminoglycosides and non-ribosomal active antibiotics. Some of the antimicrobial conjugates are prepared via “click” chemistry.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: October 6, 2015
    Assignee: Technion Research & Development Foundation Limited
    Inventors: Timor Baasov, Varvara Pokrovskaya, Valery Belakhov, Mariana Hainrichson
  • Patent number: 9114171
    Abstract: A liquid composition comprising racecadotril and cyclodextrin.
    Type: Grant
    Filed: December 23, 2013
    Date of Patent: August 25, 2015
    Assignee: McNeil-PPC, Inc.
    Inventors: Der-Yang Lee, Tusharmouli Mukherjee